C-reactive protein (CRP)-lowering agents (Q28200344)

Cardiovascular Drug Reviews

Europe PubMed Central

title

C-reactive protein (CRP)-lowering agents (English)

0 references

author name string

Kailash Prasad

series ordinal

1

0 references

language of work or name

English

0 references

publication date

2006

0 references

published in

0 references

volume

24

0 references

issue

1

0 references

page(s)

33-50

0 references

cites work

Role of C-reactive protein in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Acute-phase proteins and other systemic responses to inflammation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Regulation of complement activation by C-reactive protein

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00033.X

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Vascular inflammation and the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Candesartan Reduces Oxidative Stress and Inflammation in Patients with Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

The liver as the site of C-reactive protein formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of celecoxib on high-sensitivity C-reactive protein in chronic peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of transdermal estrogen replacement therapy on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Niacin extended-release/lovastatin: combination therapy for lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein, inflammation, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein and outcome after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effect of oxygen free radicals on cardiovascular function at organ and cellular levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein increases oxygen radical generation by neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Reduction of Serum Cholesterol and Hypercholesterolemic Atherosclerosis in Rabbits by Secoisolariciresinol Diglucoside Isolated From Flaxseed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Short-term effects of atorvastatin on C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

High-intensity statin treatment for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, random

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Intensive statin therapy--a sea change in cardiovascular prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Priapism caused by infection and an inflammatory process in the pelvic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X

Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00033.X